IO Biotech, Inc. (IOBT) News
Filter IOBT News Items
IOBT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IOBT News Highlights
- For IOBT, its 30 day story count is now at 2.
- Over the past 2 days, the trend for IOBT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about IOBT are DEC and PD.
Latest IOBT News From Around the Web
Below are the latest news stories about IO BIOTECH INC that investors may wish to consider to help them evaluate IOBT as an investment opportunity.
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialNEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win® platform, announced today that the first patient has been dosed in its Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in neoadjuvant and adjuvant patients with resectable melanoma or squamous cell carcinoma of the |
We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
IO Biotech Announces 2023 Third Quarter ResultsCompleted enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma Presented encouraging preliminary data from Phase 2 basket trial of IO102-IO103 at the IASLC 2023 World Conference on Lung Cancer (WCLC) in September 2023 and at the European Society of Medical Oncology (ESMO) annual meeting in October 2023Presented three posters at the Society for Immunotherapy of Cancer’s |
IO Biotech Appoints Helen Collins, MD, to its Board of DirectorsNEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Helen Collins, MD, to its board of directors. Dr. Collins is an industry veteran with significant experience in oncology/hematology drug development and will serve on the Research and Development Committee of the Board. “We are pleased to welcome Helen, an accompl |
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced MelanomaTrial expected to reach the primary endpoint of progression free survival in the second half of 2025 Per-protocol interim analysis expected in mid-2024 NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced today that it has completed enrollment in the pivotal Phase 3 clinical trial for IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 |
IO Biotech Announces Participation in Upcoming Investor ConferencesNEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences: Event: Jefferies London Healthcare ConferenceLocation: LondonOne-on-one meetings: Wednesday, November 15, 2023Participants: Mai-Britt Zocca, PhD, President and CEO and Amy Sullivan, CFO Event: Piper Sandler 35th Healthcar |
This IO Biotech Insider Increased Their Holding In The Last YearFrom what we can see, insiders were net buyers in IO Biotech, Inc.'s ( NASDAQ:IOBT ) during the past 12 months. That... |
IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNon-clinical data demonstrate clear impact of immune modulating vaccines targeting IDO1 and PD-L1 on several tumoral immune escape mechanisms in the tumor microenvironment (TME) leading to enhanced anti-tumor effectNEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, today announced three poster presentations at the Society for Immunotherapy of |
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An AnalysisNEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ... |
Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) CongressNEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced encouraging preliminary data from the company’s Phase 2 basket trial of IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) (IOB-022/KN-D38) at the ESMO Congress being held in Madrid from October 20-24, 2023. Jonathan Riess, MD, lead investigator of the trial at the UC Davis Com |